Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quality of Life | 43 | 2025 | 1265 | 5.580 |
Why?
|
| Surveys and Questionnaires | 29 | 2026 | 2789 | 2.450 |
Why?
|
| Sickness Impact Profile | 16 | 2013 | 46 | 2.430 |
Why?
|
| Psychometrics | 23 | 2026 | 396 | 2.220 |
Why?
|
| Health Surveys | 11 | 2023 | 319 | 1.970 |
Why?
|
| Self Report | 10 | 2020 | 394 | 1.720 |
Why?
|
| Disability Evaluation | 6 | 2017 | 216 | 1.210 |
Why?
|
| Reproducibility of Results | 17 | 2026 | 1715 | 1.180 |
Why?
|
| Factor Analysis, Statistical | 8 | 2020 | 102 | 1.130 |
Why?
|
| Immunocompromised Host | 2 | 2026 | 104 | 1.110 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2023 | 146 | 1.090 |
Why?
|
| Health Status | 10 | 2025 | 448 | 1.040 |
Why?
|
| Health Status Indicators | 3 | 2015 | 94 | 1.020 |
Why?
|
| Models, Statistical | 4 | 2020 | 309 | 0.960 |
Why?
|
| Data Collection | 4 | 2014 | 384 | 0.940 |
Why?
|
| Adult | 37 | 2026 | 17511 | 0.900 |
Why?
|
| Middle Aged | 39 | 2026 | 18439 | 0.890 |
Why?
|
| Headache | 4 | 2025 | 58 | 0.810 |
Why?
|
| Aged | 35 | 2025 | 15089 | 0.810 |
Why?
|
| Cost of Illness | 5 | 2016 | 169 | 0.770 |
Why?
|
| Pharyngitis | 1 | 2023 | 14 | 0.770 |
Why?
|
| Male | 44 | 2026 | 31295 | 0.750 |
Why?
|
| Smoking | 3 | 2020 | 863 | 0.750 |
Why?
|
| Chronic Disease | 7 | 2023 | 744 | 0.750 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 1567 | 0.740 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 90 | 0.720 |
Why?
|
| Multiple Chronic Conditions | 1 | 2022 | 40 | 0.700 |
Why?
|
| Activities of Daily Living | 9 | 2012 | 294 | 0.690 |
Why?
|
| Humans | 59 | 2026 | 65650 | 0.660 |
Why?
|
| Female | 39 | 2026 | 34309 | 0.660 |
Why?
|
| Mindfulness | 1 | 2021 | 72 | 0.640 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 161 | 0.640 |
Why?
|
| Cause of Death | 1 | 2020 | 221 | 0.610 |
Why?
|
| Adolescent | 18 | 2026 | 6350 | 0.610 |
Why?
|
| Software | 3 | 2012 | 401 | 0.600 |
Why?
|
| Prostatic Neoplasms | 3 | 2020 | 501 | 0.580 |
Why?
|
| Aged, 80 and over | 15 | 2025 | 5656 | 0.570 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 181 | 0.550 |
Why?
|
| Young Adult | 11 | 2025 | 4855 | 0.500 |
Why?
|
| Knee Injuries | 1 | 2017 | 49 | 0.490 |
Why?
|
| Fatigue | 2 | 2014 | 114 | 0.490 |
Why?
|
| United States | 16 | 2026 | 8166 | 0.470 |
Why?
|
| Heart Failure | 3 | 2023 | 965 | 0.460 |
Why?
|
| Osteoarthritis | 3 | 2020 | 146 | 0.460 |
Why?
|
| Translating | 1 | 2015 | 21 | 0.440 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 135 | 0.430 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2013 | 346 | 0.430 |
Why?
|
| Comorbidity | 7 | 2020 | 1120 | 0.420 |
Why?
|
| Drug Therapy | 1 | 2014 | 56 | 0.410 |
Why?
|
| Information Systems | 1 | 2013 | 28 | 0.390 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 2730 | 0.390 |
Why?
|
| Musculoskeletal Diseases | 2 | 2020 | 105 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 809 | 0.360 |
Why?
|
| User-Computer Interface | 2 | 2012 | 127 | 0.360 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 56 | 0.350 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 254 | 0.350 |
Why?
|
| Research Design | 2 | 2014 | 590 | 0.350 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 401 | 0.350 |
Why?
|
| Models, Theoretical | 4 | 2015 | 274 | 0.340 |
Why?
|
| Outpatients | 1 | 2012 | 143 | 0.330 |
Why?
|
| Treatment Outcome | 8 | 2017 | 5820 | 0.320 |
Why?
|
| Calibration | 4 | 2015 | 69 | 0.310 |
Why?
|
| Mental Health | 5 | 2020 | 364 | 0.300 |
Why?
|
| Anemia | 1 | 2010 | 132 | 0.300 |
Why?
|
| United Kingdom | 2 | 2026 | 86 | 0.290 |
Why?
|
| Stress, Psychological | 2 | 2021 | 475 | 0.260 |
Why?
|
| Restless Legs Syndrome | 1 | 2007 | 7 | 0.250 |
Why?
|
| Subacute Care | 1 | 2007 | 9 | 0.250 |
Why?
|
| Migraine Disorders | 2 | 2003 | 46 | 0.240 |
Why?
|
| Managed Care Programs | 2 | 2004 | 86 | 0.240 |
Why?
|
| Longitudinal Studies | 5 | 2017 | 1288 | 0.230 |
Why?
|
| Disease Management | 1 | 2007 | 235 | 0.220 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 108 | 0.220 |
Why?
|
| Program Evaluation | 1 | 2007 | 498 | 0.220 |
Why?
|
| Cough | 2 | 2024 | 183 | 0.210 |
Why?
|
| Affective Symptoms | 1 | 2004 | 17 | 0.210 |
Why?
|
| Low Back Pain | 1 | 2025 | 113 | 0.210 |
Why?
|
| Computer Systems | 1 | 2003 | 13 | 0.200 |
Why?
|
| Hyperkalemia | 1 | 2023 | 20 | 0.200 |
Why?
|
| Analysis of Variance | 2 | 2016 | 606 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 733 | 0.200 |
Why?
|
| Double-Blind Method | 6 | 2014 | 745 | 0.200 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2003 | 3 | 0.200 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 326 | 0.190 |
Why?
|
| Rehabilitation | 1 | 2003 | 7 | 0.190 |
Why?
|
| Psoriasis | 1 | 2004 | 59 | 0.190 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 163 | 0.190 |
Why?
|
| Interpersonal Relations | 2 | 2019 | 161 | 0.190 |
Why?
|
| Multimorbidity | 1 | 2022 | 53 | 0.180 |
Why?
|
| Pandemics | 1 | 2026 | 691 | 0.170 |
Why?
|
| Infant | 1 | 2026 | 1711 | 0.170 |
Why?
|
| Life Tables | 1 | 2020 | 23 | 0.170 |
Why?
|
| Marital Status | 1 | 2020 | 44 | 0.170 |
Why?
|
| Confidence Intervals | 3 | 2013 | 237 | 0.160 |
Why?
|
| Child, Preschool | 1 | 2026 | 2076 | 0.160 |
Why?
|
| SEER Program | 1 | 2020 | 75 | 0.160 |
Why?
|
| Finasteride | 2 | 2012 | 7 | 0.160 |
Why?
|
| Asthma | 1 | 2025 | 485 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 555 | 0.160 |
Why?
|
| Child | 3 | 2026 | 4634 | 0.150 |
Why?
|
| Depression | 1 | 2007 | 908 | 0.150 |
Why?
|
| Medicare | 1 | 2004 | 629 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 875 | 0.150 |
Why?
|
| Japan | 3 | 2023 | 67 | 0.150 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 552 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 318 | 0.140 |
Why?
|
| Social Support | 1 | 2021 | 394 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1026 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2019 | 191 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 42 | 0.120 |
Why?
|
| Age Factors | 1 | 2020 | 1592 | 0.120 |
Why?
|
| Personal Satisfaction | 2 | 2014 | 82 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 326 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2012 | 593 | 0.120 |
Why?
|
| Germany | 1 | 2015 | 57 | 0.110 |
Why?
|
| Thyroid Diseases | 1 | 2015 | 29 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2496 | 0.110 |
Why?
|
| Self-Assessment | 2 | 2007 | 60 | 0.110 |
Why?
|
| Single-Blind Method | 1 | 2015 | 142 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 33 | 0.110 |
Why?
|
| Concept Formation | 1 | 2014 | 19 | 0.110 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 279 | 0.110 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tobacco Products | 1 | 2015 | 63 | 0.110 |
Why?
|
| Somatostatin | 1 | 2014 | 21 | 0.100 |
Why?
|
| Goiter | 1 | 2014 | 9 | 0.100 |
Why?
|
| Smoking Prevention | 1 | 2015 | 163 | 0.100 |
Why?
|
| Methotrexate | 2 | 2006 | 80 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2113 | 0.100 |
Why?
|
| Antirheumatic Agents | 3 | 2007 | 227 | 0.100 |
Why?
|
| Patient Preference | 1 | 2014 | 87 | 0.100 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 11 | 0.090 |
Why?
|
| Computers, Handheld | 1 | 2012 | 37 | 0.090 |
Why?
|
| Emotions | 1 | 2014 | 235 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 884 | 0.090 |
Why?
|
| Dyspnea | 1 | 2012 | 120 | 0.090 |
Why?
|
| Role Playing | 1 | 2010 | 8 | 0.080 |
Why?
|
| Stroke | 1 | 2020 | 1221 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2013 | 284 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2017 | 2639 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 3329 | 0.080 |
Why?
|
| Risk Factors | 1 | 2020 | 5466 | 0.080 |
Why?
|
| Prevalence | 2 | 2012 | 1453 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2014 | 762 | 0.080 |
Why?
|
| Immunoconjugates | 2 | 2007 | 95 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 442 | 0.070 |
Why?
|
| Models, Psychological | 2 | 2010 | 102 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 462 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 28 | 0.060 |
Why?
|
| International Cooperation | 2 | 2006 | 87 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 707 | 0.060 |
Why?
|
| Program Development | 1 | 2007 | 208 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2007 | 535 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2004 | 49 | 0.050 |
Why?
|
| Potassium | 1 | 2023 | 98 | 0.050 |
Why?
|
| Intellectual Property | 1 | 2003 | 5 | 0.050 |
Why?
|
| Telephone | 1 | 2003 | 123 | 0.050 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 2002 | 6 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 27 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2002 | 22 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 42 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2002 | 46 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 663 | 0.050 |
Why?
|
| Time Factors | 2 | 2007 | 3777 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2002 | 94 | 0.050 |
Why?
|
| Intermittent Claudication | 1 | 2002 | 53 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 159 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 64 | 0.040 |
Why?
|
| Communication | 1 | 2007 | 606 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 254 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2002 | 202 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2003 | 296 | 0.040 |
Why?
|
| Social Participation | 1 | 2020 | 15 | 0.040 |
Why?
|
| Walking | 1 | 2002 | 247 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 64 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2020 | 58 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1172 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 472 | 0.040 |
Why?
|
| Cognition | 1 | 2003 | 511 | 0.040 |
Why?
|
| Hypertension | 1 | 2004 | 616 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 805 | 0.030 |
Why?
|
| Pain | 1 | 2020 | 400 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 1052 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 267 | 0.030 |
Why?
|
| Abatacept | 2 | 2007 | 67 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 56 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2011 | 26 | 0.020 |
Why?
|
| Educational Status | 1 | 2011 | 279 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 147 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2011 | 214 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 123 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2010 | 80 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 413 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 73 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 371 | 0.010 |
Why?
|
| Los Angeles | 1 | 2004 | 14 | 0.010 |
Why?
|
| Chicago | 1 | 2004 | 26 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 61 | 0.010 |
Why?
|
| Specialization | 1 | 2004 | 82 | 0.010 |
Why?
|
| Medicine | 1 | 2004 | 53 | 0.010 |
Why?
|
| Fee-for-Service Plans | 1 | 2004 | 71 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 48 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 260 | 0.010 |
Why?
|
| Europe | 1 | 2004 | 199 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 498 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 405 | 0.010 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2002 | 7 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 161 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 197 | 0.010 |
Why?
|
| Etanercept | 1 | 2002 | 33 | 0.010 |
Why?
|
| Exercise Test | 1 | 2002 | 257 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 344 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2004 | 725 | 0.010 |
Why?
|